Financial Analysis: BioCryst Pharmaceuticals (BCRX) vs. Its Rivals

BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare BioCryst Pharmaceuticals to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	$263.86 million	-5.38
BioCryst Pharmaceuticals Competitors	$698.13 million	$10.43 million	-15.41

BioCryst Pharmaceuticals has higher revenue and earnings than its rivals. BioCryst Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ rivals have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for BioCryst Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1	2	6	0	2.56
BioCryst Pharmaceuticals Competitors	9846	15131	45507	1589	2.54

BioCryst Pharmaceuticals presently has a consensus target price of $20.38, indicating a potential upside of 166.86%. As a group, “Biotechnology” companies have a potential upside of 98.03%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares BioCryst Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-37.40%	-94.24%	69.12%
BioCryst Pharmaceuticals Competitors	-12,359.35%	-203.09%	-30.93%

Insider and Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioCryst Pharmaceuticals beats its rivals on 10 of the 13 factors compared.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.